1Y Close · As of Aug 26, 2026
Cytogen operates in the Professional Services sector.
Legal name: Cytogen, Inc.
In fiscal year 2025, Cytogen (217330) reported revenue of 26.1 billion KRW, up 138.8% from 10.9 billion KRW a year earlier.
Operating profit was -8.2 billion KRW and net income was -12.3 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 76.3 billion KRW, with a P/B of 2.12.
These figures can be verified in the DART filing (receipt no. 20260320001280).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 26.1B | -8.2B | -12.3B |
| 2024 | 10.9B | -10.7B | -17.1B |
| 2023 | 3.2B | -11.8B | -15.8B |
| 2022 | 761M | -11.5B | -18.8B |
| 2021 | 348M | -12.9B | -10.9B |
Recent Filings
Officer/Major Shareholder Trading Plan Report
Large Shareholding Report (General)
Semi-Annual Report (2026.06)
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-27 | Officer/Major Shareholder Trading Plan Report |
| 2026-08-13 | Large Shareholding Report (General) |
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-08-10 | Extraordinary Meeting Result |
| 2026-08-10 | Stock Option Grant Report |